Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 12, p. e929, doi. 10.1016/j.clml.2021.07.006
- By:
- Publication type:
- Article